

GOVERNMENT OF PAKISTAN
THE PATENT OFFICE
2nd Floor, Kandawala Building,
M.A. Jinnah Road,
Karachi

No.2/2/2003-F.Sec.

Dated: 20-2-2008

To,

The Manager,
Printing Corporation of Pakistan Press,
University Road,
Karachi

Subject: **WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 15-12-2007 TO BE PUBLISHED ON 20-2-2008 IN
THE GAZETTE OF PAKISTAN PART-V.**

A manuscript copy of the weekly notification regarding application filed application accepted and scaling fee due etc., is forwarded herewith to be published in the next issue of the Gazette of Pakistan Part-V without fail.

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

| | | |
|-----------|---|---|
| 1439/2007 | <u>10-12-2007</u> Wyeth. USA. Priority (12-12-06 USA) | “Cyclic sulfonamide derivatives and methods of their use” |
| 1440/2007 | Anadys Pharmaceuticals, Inc., USA. Priority (12-12-06 USA) | “5,6-dihydro-1H-pyridin-2-one compounds” |
| 1441/2007 | Solvay S.A. Belgium. Priority (22-12-06 France) | “Catalytic hydrochlorination system and process for manufacturing vinyl chloride from acetylene and hydrogen chloride in the presence of this catalytic system” |
| 1442/2007 | Single Buoy Moorings Inc. Switzerland. Priority (11-12-06 EP) | “Cryogenic transfer hose having a fibrous insulating layer and method of constructing such a transfer hose” |
| 1443/2007 | H. Lundbeck A/S. Denmark. Priority (21-12-06 USA) | “Salt forms of an alkyl sulfonamide NPY Y5 receptor ligand, and methods for their preparation” |
| 1444/2007 | Apotex Technologies Inc. Canada. Priority (19-12-06 Canada) | “Pharmaceutical acceptable salts of thymodepressin and processes for their manufacture” |
| | <u>11-12-2007</u> | |
| 1445/2007 | Infinity Discovery, Inc. USA. Priority (12-12-06 USA) | “Ansamycin formulations and methods of use thereof” |
| 1446/2007 | Nokia Corporation. Finland. Priority (13-12-06 USA) | “System and method for managing network connectivity disruptions in a multi-homed UPNP device” |
| 1447/2007 | AstraZeneca AB. Sweden. Priority (15-12-06 USA) | “Chemical compounds” |
| 1448/2007 | Bayer Schering Pharma Aktiengesellschaft. Germany. Priority (14-12-06 USA) | “Dihydropyridine derivatives as useful as protein kinase inhibitors” |
| 1449/2007 | Janssen Pharmaceutica N.V. Belgium. Priority (15-12-06 USA) | “Benzimidazole TRP VI inhibitors” |
| 1450/2007 | Matsushita Electric Industrial Co., | “Moving image coding method, moving image |

| | | |
|-----------|---|---|
| | Ltd. Japan. Priority (14-12-06 Japan) | coding device, moving image recording method, recording medium, moving image” |
| 1451/2007 | Maschinenfabrik Rieter AG. Switzerland. Priority (22-02-05 Germany) | “A drafting unit for spinning machines” |
| 1452/2007 | Maschinenfabrik Rieter AG. Switzerland. Priority (04-04-05 Germany) | “A transport belt for transporting a fibre strand” |
| | <u>12-12-2007</u> | |
| 1453/2007 | N.V. Organon. Netherlands. Priority (12-12-06 EP) | “Oral contraceptive spray” |
| 1454/2007 | Wyeth. USA. Priority (12-12-06 USA) | “Aryl sulfamide derivatives and methods of their use” |
| 1455/2007 | 1. Syngenta Participations AG Switzerland. 2. Syngenta Limited. United Kingdom. Priority (14-12-06 UK) | “Novel herbicides” |
| 1456/2007 | Zakiuddin Ahmed. PCSIR, Karachi. | “A process for the production/recovery of chromium humate (Pigment) as “Blue Coal” from chrome waste of tanneries using lignite coal” |
| 1457/2007 | Janssen Pharmaceutica N.V. Belgium. Priority (14-12-06 USA) | “Process for the preparation of piperazinyl and diazepanyl benzamide derivatives” |
| 1458/2007 | Centocor, Inc. Pennsylvania. Priority (21-12-06 USA) | “Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles” |
| 1459/2007 | AstraZeneca AB. Sweden. Priority (21-12-06 USA) | “Therapeutic agents -550” |
| 1460/2007 | AstraZeneca AB. Sweden. Priority (21-12-06 USA) | “Therapeutic agents -551” |
| 1461/2007 | 1 .Dow Corning Corporation. USA. 2. Dow Corning India Private Limited. India. Priority (12-12-06 UK) | “Granular materials for textile treatment” |
| 1462/2007 | Fives Cail Societe Anonyme. France. | “Mill for extracting sugar cane juice from a layer of products” |

| | | |
|-----------|---|---|
| | Priority (14-12-06 France) | |
| 1463/2007 | Novartis AG. Switzerland. Priority (14-12-06 EP) | “Manufacture process” |
| 1464/2007 | Sanofi-Aventis. France. Priority (26-12-2006 France) | “Derivatives of N-(amino-(hetero) aryl)-1h-pyrrolopyridine-2-carboxamides, their preparation and their application in therapeutics” |
| 1465/2007 | Sanofi-Aventis. France. Priority (14-12-06 EP) | “Sulfonyl-phenyl-2H-(1,2,4) oxadiazol-5-one derivates, processes for their preparation and their use as pharmaceuticals” |
| | <u>13-12-2006</u> | |
| 1466/2007 | Glaxo Group Limited. United Kingdom. Priority (15-12-06 GB) | “Novel compounds” |
| 1467/2007 | Novartis AG. Switzerland. Priority (15-12-06 EP) | “Organic compounds” |
| 1468/2007 | AstraZeneca AB. Sweden. Dainippon Sumitomo Pharma Co. Ltd. Japan Priority (14-12-06 USA) | “Novel compounds” |
| 1469/2007 | Nestec S.A. Switzerland. Priority (15-12-06 EP) | “Nutritional composition” |
| 1470/2007 | Mitsui Chemicals, Inc. Japan. (Priority 19-12-06 Japan) | “Composition for preventing harmful organisms” |
| | <u>14-12-2007</u> | |
| 1471/2007 | Laboratorios Almirall, S.A. Spain. Priority (22-12-06 Spain) | “New amino nicotinic and isonicotinic acid derivatives” |
| 1472/2007 | ADC GmbH. Germany. Priority (18-12-06 Germany) | Plug-in connector for printed circuit boards” |
| 1473/2007 | Takeda Pharmaceutical Company, Limited. Japan. Priority (20-12-06 USA) | “MAPK/ERK kinase inhibitors” |
| 1474/2007 | The Procter & Gamble Company. USA. | “Composition of azimilide dihydrochloride” |

| | | |
|-----------|--|--|
| | Priority (15-12-06 USA) | |
| 1475/2007 | Pfizer Inc. USA. Priority (10-04-01 UK) Divisional. | “Pharmaceutically acceptable salt of 4-phenoxy pyrazole compound” |
| 1476/2007 | <u>15-12-2007</u> Bayer Schering Pharma Aktiengesellschaft. Germany. Priority (15-12-06 EP) | “3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same” |
| 1477/2007 | Shoib Iqbal Qadri. Karachi-Pakistan. (Provisional) | “CNG dispenser digital Model 1100-I” |
| 1478/2007 | Aamer Hussain. Karachi-Pakistan. (Provisional) | “CNG dispenser digital Model 12200-I” |
| 1479/2007 | Shoib Iqbal Qadri. Karachi-Pakistan, (Provisional) | “CNG dispenser digital Model 2100-I” |
| 1480/2007 | Shoib Iqbal Qadri. Karachi-Pakistan, Provisional) | “CNG dispenser digital model 4200-I” |
| 1481/2007 | Shoib Iqbal Qadri. Karachi-Pakistan. (Provisional) | “CNG dispenser digital Model 4100-I” |
| 1482/2007 | Shoib Iqbal Qadri. Karachi-Pakistan. (Provisional) | “CNG dispenser digital Model 1200-1” |
| 1483/2007 | Trubion Pharmaceuticals. USA. | “Single-chain multivalent binding proteins with effector function” |
| 1484/2007 | DyStar Textilfarben GmbH. Germany. Priority (26-03-05 Germany) | “Reactive dyes, their preparation and their use” |
| 1485/2007 | International Institute of Cancer Immunology, Inc. Japan. Priority (28-12-06 Japan) | “HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same” |
| 1486/2007 | Pfizer Products Inc. USA. Priority (20-12-06 USA) | “Inhibitors of serine palmitoyltransferase” |

| | | |
|-----------|--|----------------------------|
| 1487/2007 | Pfizer products Inc. USA. Priority (19-12-06 USA) | “Nicotinamide derivatives” |
| 1488/2007 | 1. Medarex Inc. 2. Pfizer Inc. USA. Priority (21-12-06 USA) | “CD44 antibodies” |

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.


The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

| | | |
|----------|---|--|
| 258/2000 | F. Hoffmann-La Roche AG Switzerland | “Phenylacetamide compound” (INT: CL, Co7D 277/46) |
|----------|---|--|

139334

The present invention relates to compounds of the formula 1:



Wherein R1, R2, R3, and R4 are as defined in claim 1.
The compounds are glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

830/2001 F. Hoffmann-La
Roche AG
Switzerland

“Cyclic heptapeptide compound of α -melanocyte
stimulating hormone”

(INT: CL, Co7K 7/50)

139335

The present invention refers to peptides cyclized
disulfide or lactam bridges having melanocortin-4
receptor (MC4-R agonist activity useful for treatment of
obesity.



(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488